A new level of complexity has recently been added to estrogen signaling with the identification of a second estrogen receptor, ER␤. By screening a rat prostate cDNA library, we detected ER␤ as well as a novel isoform that we termed ER␤2. ER␤2 contains an in-frame inserted exon of 54 nucleotides that results in the predicted insertion of 18 amino acids within the ER␤ hormone-binding domain. We also have evidence for the expression of both ER␤1 and ER␤2 in human cell lines. Competition ligand binding analysis of bacterially expressed fusion proteins revealed an 8-fold lower affinity of ER␤2 for 17␤-estradiol (E 2 ) [dissociation constant (K d ϳ 8 nM)] as compared with ER␤1 (K d ϳ 1 nM). In vitro transcribed and translated ER␤1 and ER␤2 bind specifically to a consensus estrogen responsive element in a gel mobility shift assay. Furthermore, we show heterodimerization of ER␤1 and ER␤2 with each other as well as with ER␣. In affinity interaction assays for proteins that associate specifically with the hormone-binding domain of these receptors, we demonstrate that the steroid receptor coactivator SRC-1 interacts in an estrogen-dependent manner with ER␣ and ER␤1, but not with ER␤2. In cotransfection experiments with expression plasmids for ER␣, ER␤1, and ER␤2 and an estrogen-responsive element-containing luciferase reporter, the dose response of ER␤1 to E 2 was similar to that of ER␣ although the maximal stimulation was approximately 50%. In contrast, ER␤2 required 100-to 1000-fold greater E 2 concentrations for maximal activation. Thus, ER␤2 adds yet another facet to the possible cellular responses to estrogen. (Molecular Endocrinology 13: 129-137, 1999)
INTRODUCTION
The estrogen receptor (ER) is a member of the nuclear receptor superfamily of ligand-activated transcription factors that include receptors for steroid hormones, thyroid hormone, vitamin D, retinoic acid, and eicosanoids (1) (2) (3) (4) (5) (6) . After diffusion into the cell, estradiol binds to the ER, leading to ER dimerization followed by binding to a conserved estrogen responsive element (ERE) in the regulatory region of target genes. Amino acid sequence comparison of the ER with other nuclear receptors has shown that the receptor is composed of conserved functional regions. The N-terminal transactivating region (AF1) is able to activate transcription in a hormone-independent manner, and this region has been shown to be a target of the mitogenactivating protein kinase-regulatory pathway (7) . The DNA-binding domain enables the receptor to bind to its specific DNA target, the ERE. The consensus ERE consists of a palindrome of the half-site sequence 5Ј-GGTCA-3Ј separated by 3 bp. The AF2 domain is overlapped by the hormone-binding domain (HBD) and activates transcription in response to estrogen or synthetic estrogen agonists (8) .
The mechanism of transactivation by nuclear receptors has recently achieved further complexity by the discovery of an increasing number of coregulators. This group of coregulators can be subdivided into coactivators, corepressors, and integrators. The coactivators were initially biochemically identified as ERAP160 and 140 and RIP160, 140, and 80 (9, 10) by their ability to specifically interact with the HBD of the receptor in a ligand-dependent manner. Specifically for the ER, this interaction was promoted by E 2 but antiestrogens such as 4-OH-tamoxifen were able to effectively block this interaction. Yeast two-hybrid screening led to the molecular cloning of the steroid receptor coactivator (SRC) 1, which when cotransfected with nuclear receptors, including ER, was capable of augmenting ligand-dependent transactivation (11) . Subsequent cloning and sequence comparison of transcriptional intermediary factor (TIF)2 and glucocorticoid receptor interacting protein (GRIP)1 revealed GRIP1 to be the mouse homolog of human TIF2. More recently, p300/CBP cointegrator protein (p/CIP) [also receptor-associated coactivator (RAC)3 (12) and activator for thyroid hormone and retinoid receptors (ACTR) (13) ] were shown to be new members of this family (14) . Interestingly, this ER coactivator was also identified as amplified in breast cancer (A1B) (15) . In addition, the phospho-CREB-binding protein CBP and the related p300 have been demonstrated to be ERassociated proteins and involved in ligand-dependent transactivation (16, 17) . In contrast to the coactivators mentioned above, these proteins are targets of signals mediated by a variety of distinct pathways. Moreover, by interaction with components of the basal transcription machinery, these proteins are thought of as integrators of signals from these diverse pathways. This increasing number of coregulatory factors has added immensely to our understanding of how steroids such as E 2 are able to alter the expression of specific genes at the molecular level.
Recently, a new member of the nuclear receptor family with high homology to ER was cloned from rat, mouse, and human and was termed ER␤ (18) (19) (20) . The homology to the rat ER protein (now ER␣) was shown to be 95% in the DNA-binding domain and 55% in the HBD (18) . In situ hybridization studies in rat revealed a prominent expression of this novel receptor in the epithelial cells of the secretory alveoli of the prostate and the granulosa cells of the primary, secondary, and mature follicles of the ovary. ER␤ was found to bind E 2 with high affinity and in transient transfection experiments ER␤ was capable of activating transcription of a reporter gene in an estrogen-dependent manner.
Recently, a partial clone for an alternative splice variant of ER␤2 has been described (21) . Here we report the complete cloning and functional analysis of this novel rat ER␤ isoform.
RESULTS

Cloning of ER␤2, an Alternative Splice Variant of ER␤
To obtain clones of ER␤ we screened a gt11 rat prostate cDNA library with two oligonucleotide probes derived from the published ER␤ sequence, corresponding to the nucleotides 418-477 and 1248-1307. Primary screening of ϳ900,000 phage revealed four positive plaques that were confirmed in a secondary screening and isolated in a tertiary screening. Inserts of all independently isolated plaques were then subcloned and subjected to nucleotide sequencing. The full-length cDNA clone diverged from the previously published rat cDNA at two positions (496 T to A; 729 C to G). These nucleotide changes result in amino acid changes that are conserved in the published sequence of human ER␤. Therefore, it is likely that these result from polymorphisms in the ER. More interestingly, three of four independent clones revealed an insertion of 54 nucleotides at position 1374 of the previously published rat cDNA (Fig. 1) . This results in an in-frame insertion of 18 amino acids in the predicted HBD of this receptor. We therefore termed this alternative splice variant ER␤2, ER␤1 being the originally published sequence. The amino acid sequence of this insert exhibits no homology to known proteins or peptide motifs when computer database searches were performed. Recently, the sequence of ER␤2 was also reported as an ER␤ splice variant (21) .
Expression of ER␤1 and ER␤2 in Different Human Cancer Cell Lines
Since screening of the prostate cDNA library revealed that the majority of clones (3/4) encode ER␤2, we examined the expression pattern of this nuclear receptor splice variant in a variety of human cancer cell lines derived from breast, uterus, ovary, and prostate tissue. We isolated RNA from these cells, subjected it to RT using oligo dT primers, and performed PCR reactions with primers derived from the human ER␤ sequence flanking the insertion site of the 18 amino acids (aa) in the ER␤ sequence. ER␣-specific primers and primers from the ␤2-microglobulin gene were used to control for the quality of the cDNA. As shown in Fig. 2 , as expected, all cDNAs revealed a product for the ubiquitously expressed ␤2-microglobulin (lower panel). The ER␣ transcript was detectable in breast cancer cell lines previously described as ER␣-positive such as MCF7, T47D, and BT-20 as well as in the endometrial cancer cell line ECC1 and in the ovarian cancer cell line OVCAR-3. When the PCR reaction was performed with ER␤-specific primers, a band corresponding to the expected size for the previously published ER␤ sequence was detectable in the breast cancer cell lines BT-20, MDA-MB231, and T47D and in primary normal human mammary epithelial cells (HMECs). Moreover, a transcript for ER␤1 was detectable in the ovarian cancer cell lines OVCAR-3 and UPN36T. Among endometrium cancer cell lines tested, only the ER␣-negative Ishikawa cell line showed an ER␤1 transcript. The human prostate cancer cell lines, PC-3 and DU145, were also positive for ER␤1 expression. To confirm that the bands indeed correspond to ER␤, we transferred the PCR products onto nitrocellulose and subjected it to Southern blot analysis with a radiolabeled nucleotide probe derived from the previously pub- The upper panel shows the functional domains of the previously published rat ER␤ deduced from its homology to ER␣. Numbers indicate amino acids as described (18) . The lower panel shows the amino acid sequence encoded by the 54-nucleotide insert found in ER␤2.
lished ER␤ sequence. As shown in Fig. 2 , the band of ϳ340 bp was indeed reactive with this probe. Interestingly, using PCR primers flanking the insertion in the rat cDNA also revealed a band with the expected size for ER␤2 in the human ovarian cancer cell line OVCAR-3 and the osteosarcoma cell line U2OS. To confirm the origin of this PCR product as ER␤2, we probed duplicate blots with an oligonucleotide probe corresponding to the unique 54 nucleotides of the ER␤2 sequence as shown in Fig. 2 , top panel. These data indicate that although ER␤1 is present in a variety of different cells, the ER␤2 transcript is restricted to a minority of these cell lines, suggesting a specific mechanism regulating expression of these splice variants.
ER␤2 Binds Estradiol with Lower Affinity Than ER␤1
Since insertion of the 18 aa in ER␤2 occurs in the predicted hormone-binding domain of this receptor, we first examined the binding affinity of estradiol for ER␤1 and ER␤2. Therefore, [ 3 H]E 2 was used to conduct competition ligand-binding studies of ER␤1 and ER␤2. Using bacterial expressed glutathione S-transferase (GST) fusion proteins containing the HBDs of both receptors, dissociation constants (K d ) for E 2 were 1 nM for ER␤1 but 8-fold higher (K d ϭ 8 nM) for ER␤2 (Fig. 3 ). These data indicate that the 18-aa insertion in the HBD of ER␤2 lowers its affinity for E 2 .
ER␤2 Binds to an ERE
It has been previously shown that ER␤1 is capable of binding to a consensus ERE with high affinity. To test whether the 54-nucleotide insertion of ER␤2 had an influence on DNA binding, we conducted electrophoretic mobility shift assays (EMSAs). Receptors were expressed in vitro to comparable levels (data not shown). As demonstrated in Fig. 4 , both ER␤1 and ER␤2 were able to bind specifically to the ERE probe in a hormone-dependent manner, under the stringent conditions used (22) . Specificity of binding was confirmed by the fact that unlabeled ERE could compete for binding of all receptors to the labeled probe (lanes 5), whereas competition with a mutated ERE (lanes 6), or an unrelated AP-1 sequence (lanes 7), did not have an influence on binding.
When EMSA was performed with increasing E 2 concentrations (lanes 2-4), it was interesting to note that maximal binding of ER␣ (to the ERE) occurred at the lowest concentration of E 2 used (1 nM) (lane 2), whereas both ER␤1 and ER␤2 showed a dose response with maximal binding at 100 nM. Despite the apparent differences in hormone binding affinity for ER␤1 and ER␤2, both receptors bound with similar affinity to DNA.
Heterodimerization Occurs between ER␣ and Both ER␤ Isoforms
Since it has been demonstrated that ER␣ and ER␤1 are capable of forming heterodimers upon ligand binding, we set forth to investigate whether the newly identified splice variant of ER␤ also forms heterodimers with ER␣. Therefore, we performed EMSA on a labeled ERE probe using in vitro translated fulllength receptors in the presence of 100 nM E 2 (Fig. 5) . When ER␣ (lanes 1 and 2), ER␤1 (lanes 3 and 4), or ER␤2 (lanes 5 and 6) were incubated with the labeled ERE probe, antibodies specific for ER␣ or ER␤ were able to supershift the homodimeric ER/DNA complexes (lanes 2, 4, and 6). When in vitro translated ER␣ and ER␤1 (lanes 7-10) or ER␣ and ER␤2 (lanes [11] [12] [13] [14] were coincubated with the labeled probe, each antibody was able to shift the protein/DNA complex to a different size than the respective homodimeric receptor (lanes 8, 9 and 12, 13). When both antibodies were coincubated either with ER␣/ER␤1 or with ER␣/ER␤2, a supershifted band was detected, indicating that indeed ER␣ forms heterodimers on DNA with ER␤1 and ER␤2 (lanes 10 and 14) . Heterodimers could be detected at E 2 concentrations as low as 1 nM (data not shown).
Interaction of SRC1 with ER␣ and ER␤1, but Not ER␤2
The role of putative coactivators in the hormonedependent transcriptional regulation by ER␤1 and ER␤2 was addressed by affinity purification of ER␤1-and ER␤2-associated proteins. The HBD of these receptors was fused to GST and used to purify proteins from the metabolically labeled human breast cancer cell line MCF-7 (Fig. 6) , the human breast cancer cell line MDA-MB231, and the human osteosarcoma cell line U2OS (data not shown). In the case of ER␣ (lanes 1-3), previously described proteins bound GST-HBD-ER␣ in the presence of E 2 (lane 2), but not in its absence (lane 1) nor in the presence of the ER antagonist tamoxifen (lane 3). Using the GST-HBD-ER␤1 fusion protein as an affinity matrix (lanes 4-6), only the Radiolabled ERE probe was incubated with in vitro translated ER␣ (lanes 1 and 2), ER␤1 (lanes 3 and 4), or ER␤2 (lanes 5 and 6) either in the absence (lanes 1, 3, and 5) or in the presence (lanes 2, 4, and 6) of specific antibodies. Similarly, cotranslated ER␣/ER␤1 was incubated with the ERE probe in the absence (lane 7) or in the presence of an ER␣-specific antibody (lane 8), an ER␤-specific antibody (lane 9), or both (lane 10). The same experiment was performed using cotranslated ER␣ and ER␤2 (lanes 11-14) . Whole cell extracts of MCF-7 cells were metabolically labeled with [
35 S]methionine and were bound to the GST-HBD fusion of ER␣ (lanes 1-3) , ER␤1 (lanes 4-6), and ER␤2 (lanes 7-9). The fusion proteins were previously immobilized on glutathione-Sepharose in the absence (lanes 1, 4, and 7) or the presence (lanes 2, 5, and 8) of 1 mM17␤-estradiol (E) or 4-OH-tamoxifen (T) (lanes 3, 6, and 9 ). Proteins were eluted in SDS/sample buffer and were resolved on 7.5% SDS/PAGE. ERAP160/SRC1 family of proteins could be detected (lane 5). Interestingly, when performing this experiment with the same amount of GST-HBD-ER␤2, we were unable to detect associated proteins that specifically interact with ER␤2 (lane 8 (Fig. 7A ). For this purpose we used whole-cell extracts from MCF-7 cells. Cell lysates were incubated with the GST-HBD affinity matrices of the different receptors in the absence or presence of increasing amounts of E 2 (1 M and 10 M) or 4-OHTamoxifen (1 M). Specifically bound proteins were resolved by SDS-PAGE and transferred onto nitrocellulose. Immunoblotting with a monoclonal antibody directed against human SRC1 revealed significant SRC1 binding only for GST-HBD-ER␣ and GST-HBD-ER␤1 in the presence of E 2 but not for GST-HBD-ER␤2 (Fig. 7A) . Negative control samples consisting of glutathionesepharose or GST immobilized on glutathione sepharose did not show binding (data not shown). To confirm these results, we tested the ability of recombinant SRC1 to interact with ER␤1 or ER␤2. Again, in vitro synthesized [ 35 S] methionine-labeled SRC1 associated specifically in an E 2 dependent manner only with GST-HBD-ER␣ (lane 2) and GST-HBD-ER␤1 (lane 5) but not GST-HBD-ER␤2 (lane 8) (Fig. 7B) .
Transcriptional Activity of ER␤2 on an ERE
To investigate whether an ERE can mediate transcriptional activity of ER␤2, we used a luciferase reporter gene containing two copies of an ERE and the viral thymidine kinase promoter, driving the expression of the luciferase reporter gene for transactivation studies. We performed cotransfection experiments in which U2OS cells were transfected with either an expression plasmid for ER␣, ER␤1, or ER␤2 and the estrogenresponsive reporter gene construct. E 2 maximally stimulates ER␣-mediated transactivation through an ERE of approximately 6-fold at a doses as low as 0.1 nM (Fig. 8) . ER␤1 was less potent in stimulating transcription through an ERE with only 50% of the maximal level seen with ER␣, although transcriptional activation occurs with a similar dose response. In contrast, when the same experiment was performed with an expression plasmid for ER␤2, E 2 failed to stimulate transactivation through the ERE at 0.1 nM or 1 nM E 2 (Fig.  8) . Increasing doses of E 2 to 100 nM were able to stimulate ER␤2-mediated activation to a level comparable ER␤1 (Fig. 8) . These data indicate that ER␤2 requires 100-to 1000-fold higher concentrations of E 2 to stimulate transcription to the same extent as ER␤1.
DISCUSSION
Estradiol mediates its diverse biological effects by binding to the ER, thereby allowing the receptor to 
. SRC1 Associates with GST-HBD-ER␣ and GST-HBD-ER␤1, but Not with GST-HBD-ER␤2
A, Whole-cell extracts from the human breast cancer cell line MCF-7 were incubated with GST-HBD-ER␣ (top panel),
GST-HBD-ER␤1 (middle panel), and GST-HBD-ER␤2 (bottom panel) immobilized on glutathione-Sepharose in the absence (lane 1) or presence of 1 M E 2 (lane 2), 10 M E 2 (lane 3), or 1 M 4-OH-tamoxifen (T) (lane 4)
. Specifically associated proteins were recovered by boiling in SDS/sample buffer, resolved on 7.5% SDS/PAGE, and transferred to nitrocellulose. Filters were cut and probed with an SRC1 monoclonal antibody, and specifically bound primary antibody was detected with peroxidase-coupled secondary antibody and chemiluminescence. B, Recombinant 35 S-labeled SRC1 produced by in vitro transcription/translation in a rabbit reticulocyte lysate was bound to GST-HBD-ER␣ (lanes 1-3) , GST-HBD-ER␤1 (lanes 4-6), and GST-HBD-ER␤2 (7-9) immobilized on glutathione-linked Sepharose in the absence (lanes 1, 4, and 7) or presence of 1 M estradiol (lanes 2, 5, and 8) and 1 M tamoxifen (lanes 3, 6, and 9). The translation product (15 ml) was incubated with the different affinity matrices that had been blocked with 3% BSA under the indicated conditions at 4 C for 30 min. After extensive washing, bound proteins were eluted in 20 mM reduced glutathionecontaining elution buffer (120 mM NaCl/100 mM Tris-HCl, pH 8.0) and separated by 7.5% SDS-PAGE. Gels were treated with a fluorophore, dried, and visualized by autoradiography.
bind to and activate transcription through estrogenresponsive elements in the promoter region of target genes. The phenotype of ER␣ knockout mice pointed to the potential existence of an alternative mediator for E 2 action (23). Recently, a new member of the nuclear receptor family with very high homology to ER␣ was cloned and termed ER␤ (18) . The identification of ER␤ has added a new level of complexity to E 2 signaling.
In this report we describe the cloning of an alternative splice variant of ER␤, ER␤2, which contains an 18-aa insert in the predicted hormone binding domain of this nuclear receptor, adding yet another level of complexity to E 2 signaling. We have demonstrated that this isoform is expressed in normal rat prostate as well as various human cancer cell lines. The fact that in some cell lines one isoform appears to be more prominent than the other, and that this relative ratio varies from tissue to tissue examined, suggests a specific mechanism regulating expression of one or the other splice variant.
Interestingly, we demonstrate that both receptors coexist in certain cells and can heterodimerize on the ERE. Further complexity is achieved, since not only do ER␤1 and ER␤2 heterodimerize, but each can also heterodimerize with ER␣. Since we could not demonstrate that ER␤2 binds the coactivator SRC1 one could speculate that heterodimerization of ER␣ or ER␤1 with ER␤2 regulates the recruitment of this coactivator to the transcriptional complex. Since previous studies have demonstrated that other transcriptional cointegrators, namely p300 and the phospho-CREB binding protein (CBP) appear to be rate limiting for active transcription (16) , this reduction of SRC1 recruitment might reduce transcriptional activity through the ERE.
Another recent study has shown that while both ER␣ and ER␤1 activate E 2 -mediated transcription through an ERE, they exert opposite effects through an AP-1 site (24) . While E 2 stimulates ER␣-mediated transcription through an AP-1 site, E 2 inhibits ER␤1-mediated transcription through the same response element. It still has to be demonstrated which effect ER␤2 mediates through an AP-1 site, and which effect the different heterodimers of these receptors mediate through this response element in the presence of different ligands.
Interestingly, alignment of the ER␣ sequence with ER␤, as compared with the predicted structure of nuclear receptors, indicates that the 18-aa insert in ER␤2 lies in helix 6 of this receptor. This relatively nonconserved region among different nuclear receptors follows immediately after the ␣-turn within the ligand binding domain of the receptor (25) . The addition of 18 aa in this region might distort the correct conformation of this receptor for high-affinity E 2 binding as supported by our E 2 binding data. High physiological E 2 concentrations achieved especially in the ovary during pregnancy or the periovulatory phase might be sufficient to activate ER␤2. Another interesting possibility is that this insertion creates a new conformational change required for high-affinity binding of a yet unidentified ligand other than E 2 .
With respect to the basic mechanisms by which nuclear receptors initiate transcription of their target genes, much of recent research in the field has focused on so-called coactivators of these proteins, which bind the nuclear receptors in a ligand-dependent manner to augment AF-2-mediated transactivation. The coactivators have been identified by the in vitro interaction of the ligand-binding domain of ER␣ fused to GST as an affinity matrix for proteins interacting in an E 2 dependent manner (9, 10) . Using the same approach we could demonstrate the interaction of the coactivator of nuclear receptors, SRC1 with both ER␣ and ER␤1. Interestingly, GST fusion proteins of both the ligand-binding domain and the full-length ER␤2 failed to interact with SRC1 in a ligand-dependent manner, despite the fact that both fusion proteins were able to bind both E 2 and an ERE. It is striking that this results in a shift in the dose response of ER␤2 to E 2 but not the maximal level of activation. This suggests the possibility that under certain conditions ER␤2 might act to dampen cellular responses to estrogen.
We and others (29) have identified an alternative splice variant of ER␤ termed ER␤2. This protein exhibits interesting properties as a mediator of estrogen action and provides new complexity to the spectrum of potential cellular responses to estrogen.
MATERIALS AND METHODS
Library Screening and Plasmids
We screened a gt11 rat prostate cDNA library (CLONTECH, Palo Alto, CA), according to the manufacturers guidelines U2OS cells were transiently cotransfected with the ERE reporter plasmid and expression plasmids for either ER␣, ER␤1, or ER␤2. Cells were left untreated or treated with 0.1 nM, 1 nM, 10 nM, and 100 nM estradiol. Data were normalized as the ratio of raw light units to ␤-gal-units and expressed as the fold of induction relative to untreated controls. The data presented are the mean of three independent experiments. Error bars represent SEM. with two radiolabeled oligonucleotides corresponding to nucleotides 418-477 and 1248-1307 of the previously published rat ER␤ sequence. Labeling of the probe was performed with ␥-32 P-ATP (6000 mCi/mmol; New England Nuclear, Boston, MA) in the presence of T4 polynucleotide kinase according to standard procedures (26) . Positive plaques from the primary screening were isolated by secondary and tertiary screening, and phage DNA was obtained by boiling plaques in 100 ml H 2 O. Plaque DNA was then amplified by PCR using ER␤-specific primers corresponding to nucleotides 402-419 and 1866-1885 of the ER␤ sequence. One plaque contained the full-length ER␤ cDNA. The resulting PCR fragment was blunt ended using T4 DNA polymerase and was subcloned into the EcoRV site of pcDNA3.0 (Invitrogen, San Diego, CA), resulting in pER␤I and was completely sequenced from both strands by automated sequence analysis (ABI 3000, Molecular Biology Core Facility, Dana Farber Cancer Institute). DNA from the remaining plaques yielded PCR products when a 5Ј-primer corresponding to nucleotides 922-941 of the ER␤ sequence was used for amplification, indicating that these were partial cDNA clones. Amplification of the predicted HBD from these different clones was performed with primers 5Ј-CGTGGATCCGAGCAGGTACACTGCCTG-3Ј 5Ј-GATGAATTCTCACTGAGACTGTAGGTTC-3Ј and the resulting fragments were BamHI/EcoRI digested and subcloned into the corresponding sites of pGEX2TK (27) resulting in pGEX ER␤1HBD and pGEX ER␤2HBD. These plasmids were also subjected to complete nucleotide sequence analysis, revealing the alternative splice variant in three of these clones. To obtain the full-length ER␤2 cDNA we liberated the ER␤1 cDNA from pER␤I by EcoRI/NotI digest and subcloned the 1.4-kb insert into the corresponding sites of pBluescript SK(Ϫ), resulting in pBS ER␤1. This subclone was confirmed by partial sequence analysis. The 3Ј-sequence of ER␤2 was then liberated from the pGEX2TK ER␤2 plasmid by EcoRI digest, blunt ending, and SmaI digest and subcloned into NotI-digested, blunt ended, and then SmaI-digested pBSER␤1, resulting in pBSER␤2. Correct orientation of the 3Ј-end was confirmed by restriction analysis and confirmed by partial sequence analysis, also revealing the presence of the 54-nucleotide insert. To generate eukaryotic expression plasmids for ER␤1 and ER␤2, the corresponding cDNAs were liberated from pBSER␤1 and ER␤2 by SacII digest, blunt ending followed by XhoI digest, and subcloned into NotIdigested, blunt ended, and then XhoI-digested pcDNA 3.1(Ϫ) vector (Invitrogen), resulting in pcDNA ER␤1 and pcDNA ER␤2. To obtain full-length GST fusion proteins of ER␤1 and ER␤2 the corresponding cDNAs were PCR amplified with primers 5Ј-GAAGATCTATGACATTCTACAGTCCTGC-3Ј 5Ј-GATGAATTCTCACTGAGACTGTAGGTTC-3Ј using pBSER␤1 and ER␤2 as templates, BglII/EcoRI digested, and subcloned into BamHI/EcoRI-digested pGEX2TK plasmid, resulting in pGEX ER␤1fl and pGEX ER␤2fl. Both plasmids were verified by complete nucleotide sequence analysis.
Cells and Cell Culture
Cell lines MCF-7, BT-20, MDAMB231, T47D, ECC1, Ishikawa, PC-3, Du145, LnCAP, CV1, and U2OS were obtained from American Type Culture Collection (Manassas, VA). The normal HMECs were purchased from Clonetics (San Diego, CA). The human ovarian cancer cell lines Sw626, OVCAR-3, CAOV-3, and UPN36T were a gift from Dr. S. Cannistra. Cells were maintained in DMEM containing 10% FBS (vol/vol) (Sigma Chemical Co., St. Louis, MO) at 37 C and 5% CO 2 /95% air.
RT-PCR and Southern Blot
RNA extraction was performed using the Ultraspec RNA isolation system (Biotecx, Houston, TX) according to manufacturer's guidelines. RT was performed using oligo dT primers. Using the GIBCO BRL RT Kit (GIBCO BRL, Grand Island, NY). Two micrograms of cDNA were used as a template for PCR reactions using two microglobulin-specific primers (CLONTECH, primers specific to human ER (5Ј-GGGAGCT-GGTTCACATGATC-3Ј and 5Ј-GTCCAGGACTCGGTGGAT-ATG-3Ј) or primers specific to human ER ((5Ј-GCCTCCAT-GATGATGTCCCTG-3Ј and 5Ј-GATCATGGCCTTGACACA-GAG-3Ј). PCR cycling was performed using a touch down program: 1) 95 C, 1 min; 2) 95 C, 30 sec; 60 C, 30 sec (Ϫ0.5 C/cycle); 72 C, 2 min; 3) 72 C, 2 min, 4 C, for ever, 35 cycles, 60 C to 40 C. Resulting PCR products were subjected to electrophoresis in 2% agarose gels. In case of ER, products were transferred to nitrocellulose and probed with endlabeled oligonucleotides either common to ER␤1 and ER␤2.
(5Ј-TCCTCAGAAGACCCTCACTGGCCACGTTGCGCAG-ATGAAGAGTGCTGCCCCAAGG-3Ј) or specific for ER␤2 (5Ј-GCCAAGAAGATTCCCGGCTTTGTGGAGCTCAGCCTG-TTCGACCAAGTGCGGCTCTTGGAG-3Ј). Both were washed three times in 1ϫ saline sodium citrate, 0.1% SDS at room temperature and for 30 min in buffer containing 0.1ϫ saline sodium citrate, 0.1% SDS at 50 C.
Ligand Competition Analysis
For ligand competition studies GST HBD fusion proteins of ER␤1 and ER␤2 were diluted in HED buffer (20 mM HEPES, pH 7.4, 1 mM EDTA, 1 mM dithiothreitol) and incubated with 1 nM [ 3 H]17␤-estradiol and various concentrations of unlabeled diethylstilbestrol. The bound and unbound estrogens were separated using dextran-coated charcoal (28) . The amount of bound [ 3 H]17␤-estradiol is presented as a percent of total bound in the absence of diethylstilbestrol.
Gel Mobility Shift Assay
Recombinant ER␣, ER␤1, and ER␤2 cDNAs were transcribed and translated in vitro in TNT-T 3 coupled rabbit reticulocyte lysates (Promega, Madison, WI) from the T 3 Promoter following the manufacturer's guidelines. Typically 4 ml of programmed lysate (or 4 ml of a 1:50 dilution of the ER␤1 GST-fusion protein for ER␤1 and ER␤2 heterodimers) were used in each binding reaction. The binding reactions were carried out in binding buffer A100 (20 mM HEPES, pH 7.9, 20% glycerol, 100 mM KCl, 1 mM dithiothreitol), 0.5 mg of poly deoxyinosinic-deoxycytidylic acid, 20 mg BSA, 4 ml H 2 O, 7.5 mM MgCl 2 (final concentration), and 4 ng of probe that was labeled by end-filling with Klenow in the presence of [ 32 P]␣-dGTP. Preincubations containing ligand, antibody, and/or cold competitor as indicated were performed at room temperature for 20 min. After the incubation step the probe was added and binding was conducted for 15 min at room temperature. The entire reaction of 17 ml was loaded onto a 4% gel, and electrophoresis was carried out at 110 V for 2 h at room temperature. Gels were dried and exposed for 2-5 h at Ϫ80 C. The following antibodies were used: AER 314 (Neomarkers, Fremont, CA), mouse polyclonal serum for ER␤1 and ER␤2. We used the following oligonucleotides and their compliments as probes and competitors:
ERE, 5Ј-GATCTCTTTGATCAGGTCACTGTGACCTGACT-TTG-3Ј; mtERE, 5Ј-GATCTCTTTGATCAGGACACAGTGTCCTGA-CTTTG-3Ј; AP1, 5Ј-GAATGGTGACTCATATTTGAACAAGCCTGCAA-TGCCCAGCAGA-3Ј.
Metabolic Labeling and Protein-Protein Interaction Assay
Before the metabolic labeling, MCF-7 cells were preincubated with methionine-free DMEM for 10-20 min. Confluent 150-mm diameter dishes were labeled with 1 mCi (1 Ci ϭ 37 GBq) [
35 S]methionine (New England Nuclear, Boston, MA) for 4 h in methionine-free DMEM. After labeling cells were washed extensively with ice-cold PBS and lysed in 1 ml of buffer A (150 mM NaCl, 50 mM Tris, pH 7.4, 5 mM EDTA, 0.5% Nonidet P-40). After 30 min of rotation at 4 C, cell extracts were clarified by centrifugation at 12,000 rpm, and the supernatant was collected in a fresh tube. Lysates containing 2.5 ϫ 10 7 cpm were then incubated with a GST fusion protein containing the HBDs of either ER␣, ER␤1, or ER␤2 (GST-HBD ER␣, ER␤1, or ER␤2) immobilized on 50 ml of glutathioneSepharose beads in the presence or absence of the appropriate ligand in buffer B (150 mM NaCl, 50 mM Tris, pH 7.4, 5 mM EDTA) as previously described (9) . After washing the beads three times in 1 ml of buffer B and once in 1 ml of buffer A, proteins were eluted in SDS/sample buffer and resolved on 7.5% SDS/PAGE. Gels were fixed in 35% methanol/10% glacial acetic acid, fluorographed in Enhance solution (New England Nuclear), and dried before exposure to film.
Western Blotting
Protein-protein interaction assays were performed as described above using unlabeled cell extracts from MCF-7 cells. Proteins were resolved directly in SDS/polyacrylamide gels after boiling in SDS sample buffer. Immunodetection was performed after blocking the membranes overnight at 4 C in 20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 0.05% Tween 20, and 5% powdered milk by incubating membranes with an anti-SRC1 antibody for 2 h at room temperature. Monoclonal antibody raised against GST-SRC1 was used for immunoblot analysis in a dilution of 1:100. Specifically bound primary antibody was detected with peroxidase-coupled secondary antibody and chemiluminescence.
In Vitro Transcription and Translation
Recombinant SRC1 cDNA in pBluesript was transcribed and translated in TNT-T 3 coupled reticulocyte lysates (Promega, Madison, WI) in the presence of [ 35 S]methionine from the T 3 promoter following the manufacturer's guidelines.
Transient Transfection and Luciferase Assay
For transient transfections U2OS cells were seeded in 24-well plates in phenol red-free DMEM supplemented with 10% charcoal dextran-treated FBS. Cells at a density of 40,000/ well were transfected with 100 ng of reporter plasmid, 10 ng of receptor expression vector, 10 ng ␤Actin␤Gal plasmid and 680 or 690 ng of salmon sperm DNA to a total of 800 ng using the calcium phosphate/DNA precipitation method. After 16 h, cells were washed once with PBS and were left either untreated or treated with 0.1 nM, 1 nM, 10 nM, or 100 nM E 2 for 16 h. For luciferase assays, cells were lysed in potassium phosphate containing 1% Triton X-100. Light emission was detected using a luminometer after addition of luciferin. ␤-Gal activity was detected using the Galacto-Star (Tropix, Bedford, MA).
